Clinical trials: Nephrocalcinosis
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene.
- Conditions
- Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia
- Trial name
- RICHH (NCT03301038)
- Testing
- Rifampin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Philadelphia
Primary Hyperoxaluria, Nephrocalcinosis
International Registry for Primary Hyperoxaluria
The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria.
- Conditions
- Primary Hyperoxaluria, Nephrocalcinosis, Kidney Stones
- Trial name
- NCT00875823
- Where
- 4 sites in United States
- Sponsor
- Mayo Clinic
Primary Hyperoxaluria Type 3
Natural History of Patients With PH3 and a History of Stone Events
This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence…
- Trial name
- PHYOX-OBX (NCT04542590)
- Where
- 6 sites in United States, Canada and 3 more
- Volunteers
- 7 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Autosomal Dominant Hypocalcemia (ADH)
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- Trial name
- CALIBRATE (NCT05680818)
- Testing
- Encaleret, Standard of Care
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 67 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Nephrocalcinosis
Diagnostic Work-up of Nephrocalcinosis in Children
This cross-sectional study aims to identify the underlying etiology of nephrocalcinosis and to evaluate the diagnostic work-up in infants and children presenting to Assiut University Children's Hospital.
- Trial name
- NCT07882355
- Volunteers
- 40 people
- Sponsor
- Assiut University
Idiopathic Infantile Hypercalcemia - Mild Form
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH
Idiopathic infantile hypercalcemia(IIH) is a rare,genetic disorder of mineral metabolism. Biallelic loss of functions mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for…
- Trial name
- NCT03384121
- Testing
- Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- The Hospital for Sick Children
X-linked Hypophosphatemia (XLH)
Effective Dosing of Burosumab in XLH
X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells.
- Trial name
- NCT07183579
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
Nephrocalcinosis
Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial.
- Trial name
- PRENECAL (NCT01756547)
- Testing
- Potassium Citrate
- Where
- Spain
- Volunteers
- 74 people
- Sponsor
- Juan A. Arnaiz
Nephrolithiasis, Nephrocalcinosis
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults.
- Conditions
- Nephrolithiasis, Nephrocalcinosis, Hypercalciuria
- Trial name
- FLUCOLITH (NCT04495608)
- Testing
- Fluconazole
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Nephrocalcinosis
Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset
The aim of the study is to build a database of pediatric patients affected by nephrolithiasis or nephrocalcinosis in order to investigate their clinical and epidemiological characteristics.
- Trial name
- Calcolosi-kid (NCT07874087)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Infant; Premature, Light-For-Dates
Nephrocalcinosis in Very Low Birth Weight Infants
Extremely premature children benefit from specific follow-up that requires high nutritional intake and the use of specific therapies that expose them to the risk of nephrocalcinosis.
- Trial name
- NCT04860583
- Testing
- Renal ultrasound
- Volunteers
- 265 people
- Sponsor
- Hospices Civils de Lyon
Nephrocalcinosis
Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with ~ 7-10 % of preterm infants developing…
- Trial name
- NCT00249951
- Testing
- Alkaline citrate
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University of Cologne
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Nephrocalcinosis
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital
To study prevalence, risk factors, possible etiologies, clinical presentation and outcome of nephrocalcinosis in children at Sohag University Hospital.
- Trial name
- NCT05862207
- Volunteers
- 50 people
- Sponsor
- Sohag University
Nephrocalcinosis, Preterm Infant
The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants
The study aims to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants using patient data collected during hospitalisation at the Neonatology Centre.
- Trial name
- NCT04382976
- Where
- Lithuania
- Volunteers
- 171 people
- Sponsor
- Vilnius University
Primary Hyperoxaluria
Phenotyping of Primary Hyperoxaluria
985 / 5000 Résultats de traduction Primary hyperoxaluria is a rare autosomal recessive disease with an estimated prevalence of around 1 to 3 cases per million population.
- Trial name
- PHENO-HOPLA (NCT05107830)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Strasbourg, France
Prematurity, Nephrocalcinosis
Preterm Infants and Nephrocalcinosis
Nephrocalcinosis (NC), defined as calcification of renal tissue, has been reported to occur in 7-41% of premature infants. Causes of NC are likely multi-factorial, and infants born prematurely and with very low birth weight…
- Conditions
- Prematurity, Nephrocalcinosis, Hypercalciuria
- Trial name
- NC (NCT02438267)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Utah
Autosomal Dominant Hypocalcemia
ADH1 and ADH2 Disease Monitoring Study (DMS)
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease…
- Trial name
- CLARIFY (NCT05227287)
- Where
- 27 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Nephrolithiasis
Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?
Biallelic loss-of-function variants in CYP24A1 have been identified as a common genetic cause of autosomal recessive hypercalcemia (ARH, ORPHA 300547, 1 in 80,000 live births), characterized by low PTH (parathyroid hormone)…
- Trial name
- HETEROCYP (NCT07201701)
- Testing
- Supplementary blood samples for PBMC analysis at V2
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon